<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00313872</url>
  </required_header>
  <id_info>
    <org_study_id>SMC IRB 2005-03-044</org_study_id>
    <nct_id>NCT00313872</nct_id>
  </id_info>
  <brief_title>Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer</brief_title>
  <official_title>Phase III Randomized Trial of Taxotere/Cisplatin Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      To assess the optimal sequence of the palliative chemotherapy regimen (DP --&gt; FOLFIRI vs
      FOLFIRI --&gt; DP) in metastatic gastric cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is the second leading cause of cancer death worldwide and is the most common
      malignancy in Korea. Metastatic gastric cancer remains a therapeutic challenge for medical
      oncologists due to poor prognosis. A recent phase III trial comparing
      docetaxel-cisplatin-5-FU (DCF) to the reference arm of cisplatin-5-FU (CF) showed a
      significant superiority of DCF in terms of survival, time-to-progression, and response rate.
      However, because DCF regimen was associated with high incidence of toxicities, the regimen
      has not yet been widely accepted as the standard first-line chemotherapy for gastric cancer
      patients. Thus, the optimum front-line chemotherapy regimen should be extensively
      investigated in these patients to improve survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Second progress-free survival</measure>
    <time_frame>2years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity, overall survival</measure>
    <time_frame>2years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Metastases</condition>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr, D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr
D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DP</intervention_name>
    <description>D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre &amp; Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre &amp; post hydration (if Mg &lt;WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks</description>
    <arm_group_label>DP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan</description>
    <arm_group_label>FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed metastatic adenocarcinoma of the stomach

          2. Age â‰¥ 18

          3. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

          4. Life expectancy of at least 3 months

          5. Adequate renal, liver, bone marrow functions

          6. Adjuvant chemotherapy more than 12 months from the date of study entry

          7. Written informed consent

        Exclusion Criteria:

          1. Active infection requiring antibiotics

          2. Pregnant, lactating women

          3. Brain metastasis

          4. Systemic illness not appropriate for chemotherapy

          5. Radiotherapy within 2 weeks before the study entry

          6. Allergy to drugs used in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Ki Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2006</study_first_submitted>
  <study_first_submitted_qc>April 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2006</study_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>irinotecan</keyword>
  <keyword>docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

